Clark L C, Marshall J R
Arizona Cancer Center and Arizona College of Public Health, Tucson, Arizona 85724-5024, USA.
Urology. 2001 Apr;57(4 Suppl 1):185-7. doi: 10.1016/s0090-4295(00)00970-5.
This is a report of research efforts underway at the Arizona Cancer Center. These efforts build upon Larry Clark's unanticipated clinical prevention trial results: those results indicated that 200 microg/day of selenium in selenized yeast decreased prostate cancer risk by almost 60%. The trials underway address various phases of the possible preventive activity of selenium. The first of these, for men who are suspected to have prostate cancer but who have had a biopsy revealing no evidence of cancer, will test the ability of selenium to prevent the development of clinical prostate cancer. The second is for men with high-grade prostatic intraepithelial neoplasia; the trial will test whether selenium will prevent the development of prostatic cancer in this high-risk group. The third trial is for men who have been diagnosed with prostate cancer and are scheduled for prostatectomy: the trial is designed to test whether evidence of selenium-linked changes can be identified in the tissue removed at prostatectomy. The fourth trial is for men who have been diagnosed with prostate cancer but who have chosen neither surgery nor irradiation; this trial will evaluate whether treatment with selenium will inhibit the progress of prostate cancer. Together, these trials will provide important information as to the prostate cancer chemopreventive potential of selenium.
这是一份关于亚利桑那癌症中心正在进行的研究工作的报告。这些工作建立在拉里·克拉克意外的临床预防试验结果之上：那些结果表明，硒酵母中每天200微克的硒可使前列腺癌风险降低近60%。正在进行的试验涉及硒可能的预防活性的各个阶段。其中第一个试验针对那些疑似患有前列腺癌但活检未发现癌症证据的男性，将测试硒预防临床前列腺癌发展的能力。第二个试验针对患有高级别前列腺上皮内瘤变的男性；该试验将测试硒是否能预防这个高危群体中前列腺癌的发展。第三个试验针对已被诊断患有前列腺癌且计划进行前列腺切除术的男性：该试验旨在测试在前列腺切除术中切除的组织中是否能识别出与硒相关的变化证据。第四个试验针对已被诊断患有前列腺癌但既未选择手术也未选择放疗的男性；该试验将评估硒治疗是否会抑制前列腺癌的进展。总之，这些试验将提供有关硒对前列腺癌化学预防潜力的重要信息。
